MetLife Investment Management LLC Trims Stock Holdings in Hologic, Inc. (NASDAQ:HOLX)

MetLife Investment Management LLC reduced its position in Hologic, Inc. (NASDAQ:HOLX) by 3.0% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 60,329 shares of the medical equipment provider’s stock after selling 1,877 shares during the quarter. MetLife Investment Management LLC’s holdings in Hologic were worth $4,914,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the business. Innealta Capital LLC acquired a new stake in Hologic during the 2nd quarter worth $25,000. Wolff Wiese Magana LLC purchased a new stake in shares of Hologic in the third quarter valued at about $25,000. Sunbelt Securities Inc. purchased a new stake in shares of Hologic in the second quarter valued at about $37,000. First Horizon Advisors Inc. boosted its stake in shares of Hologic by 38.3% during the third quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock worth $39,000 after buying an additional 134 shares during the period. Finally, Cromwell Holdings LLC grew its holdings in shares of Hologic by 330.2% during the third quarter. Cromwell Holdings LLC now owns 542 shares of the medical equipment provider’s stock worth $44,000 after buying an additional 416 shares during the last quarter. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

HOLX has been the subject of a number of recent research reports. Evercore ISI increased their price objective on Hologic from $78.00 to $82.00 and gave the stock an “in-line” rating in a research report on Tuesday, October 1st. Needham & Company LLC reaffirmed a “buy” rating and set a $90.00 price target on shares of Hologic in a report on Tuesday, October 15th. Raymond James boosted their price objective on shares of Hologic from $93.00 to $95.00 and gave the company an “outperform” rating in a research note on Tuesday, November 5th. JPMorgan Chase & Co. raised their target price on shares of Hologic from $92.00 to $94.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 5th. Finally, UBS Group boosted their price target on shares of Hologic from $84.00 to $90.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 5th. Four investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $89.91.

Hologic Trading Up 0.1 %

Shares of Hologic stock opened at $79.50 on Monday. The company has a 50-day moving average of $80.18 and a two-hundred day moving average of $78.47. The stock has a market cap of $18.47 billion, a PE ratio of 23.87, a price-to-earnings-growth ratio of 2.51 and a beta of 0.98. The company has a current ratio of 3.69, a quick ratio of 3.03 and a debt-to-equity ratio of 0.49. Hologic, Inc. has a 12-month low of $67.59 and a 12-month high of $84.67.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings data on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.01. The firm had revenue of $987.90 million during the quarter, compared to analysts’ expectations of $978.25 million. Hologic had a return on equity of 19.79% and a net margin of 19.59%. Hologic’s revenue was up 4.5% on a year-over-year basis. During the same period in the previous year, the firm posted $0.89 earnings per share. On average, research analysts anticipate that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.